title: Breast cancer: weekly paclitaxel--still preferred first-line taxane for mBC.
authors.affiliation: Breast Cancer Expert Centre, Medical Oncology Service, Assistance Publique-Hôpitaux de Paris (AP-HP) Tenon, Institut Universitaire de Cancérologie-Université Pierre-et-Marie-Curie (IUC-UPMC), Sorbonne University, 4 Rue de la Chine, Paris 75020, France.
authors.forename: Joseph
authors.initials: J
authors.lastname: Gligorov
authors.affiliation: Breast Cancer Expert Centre, Medical Oncology Service, Assistance Publique-Hôpitaux de Paris (AP-HP) Tenon, Institut Universitaire de Cancérologie-Université Pierre-et-Marie-Curie (IUC-UPMC), Sorbonne University, 4 Rue de la Chine, Paris 75020, France.
authors.forename: Sandrine
authors.initials: S
authors.lastname: Richard
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000068258:Bevacizumab / Q000008:administration & dosage*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D004334:Drug Administration Schedule; D004357:Drug Synergism; D005260:Female; D006801:Humans; D009362:Neoplasm Metastasis; D017239:Paclitaxel / Q000008:administration & dosage*; D016032:Randomized Controlled Trials as Topic
chemical_list: D000068258:Bevacizumab; D017239:Paclitaxel